MyFinsight
Home
Blog
About
Proceeds from
convertible notes payable,...
$8,585K
Net cash provided by
(used in) financing...
$8,359K
(3378.04%↑ Y/Y)
Canceled cashflow
$226K
Net increase
(decrease) in cash
-$416K
Canceled cashflow
$8,359K
Amortization of debt discount
$1,903K
Depreciation and
amortization
$827K
(267.56%↑ Y/Y)
Loss on issuance of
convertible debt
$422K
Accounts payable
$345K
(430.77%↑ Y/Y)
Accrued expenses and
other current...
$284K
(26.79%↑ Y/Y)
Amortization of right-of-use
asset
$155K
something is missing
$135K
Share-based compensation
and restricted...
$119K
(-59.39%↓ Y/Y)
Financing costs
$182K
Principal payments of
notes payable
$24K
(-50.00%↓ Y/Y)
Principal payment on
financing lease liability
$20K
(-31.03%↓ Y/Y)
Net cash used in
investing activities
-$6,578K
(-32790.00%↓ Y/Y)
Net cash used in
operating activities
-$2,197K
(-172.24%↓ Y/Y)
Canceled cashflow
$4,190K
Investment in bionx
(license agreement)
$6,502K
Capital expenditures
$85K
(325.00%↑ Y/Y)
Net loss
-$3,607K
Changes in fair value of
warrant liability and...
-$1,436K
(-1280.77%↓ Y/Y)
Prepaid expenses and
other assets
$491K
(104.58%↑ Y/Y)
Accounts receivable, net
$416K
(331.11%↑ Y/Y)
Partnership advance
$248K
Operating lease liability
-$144K
Accounts payable related
party
-$29K
(65.48%↑ Y/Y)
Inventory
$14K
(-80.00%↓ Y/Y)
Deferred revenue
-$2K
(-300.00%↓ Y/Y)
Back
Back
Cash Flow
NEXGEL, INC. (NXGL)
NEXGEL, INC. (NXGL)
source: myfinsight.com